Article Title | Author(s) | Issue Year |
---|---|---|
Current and future therapeutic approaches for osteosarcoma | Douglas J. Harrison, David S. Geller, Jonathan D. Gill, Valerae O. Lewis & Richard Gorlick | 2018 |
Targeted therapies in non-small-cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors | Assunta Sgambato, Francesca Casaluce, Paolo Maione & Cesare Gridelli | 2018 |
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer | Misako Nagasaka & Shirish M. Gadgeel | 2018 |
Current and future immunotherapies for thyroid cancer | Alessandro Antonelli, Silvia Martina Ferrari & Poupak Fallahi | 2018 |
Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer | Howard A. Burris III | 2018 |
Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia | Allison Barz, Caitlin W. Elgarten, Stephan A. Grupp, Shannon L. Maude & David T. Teachey | 2018 |
Targeted therapy for metastatic colorectal cancer | Timothy J. Price, Monica Tang, Peter Gibbs, Daniel G. Haller, Marc Peeters, Dirk Arnold, Eva Segelov, Amitesh Roy, Niall Tebbutt, Nick Pavlakis, Chris Karapetis, Matthew Burge & Jeremy Shapiro | 2018 |
Nivolumab for the treatment of hepatocellular carcinoma | Fabian Finkelmeier, Oliver Waidmann & Joerg Trojan | 2018 |
Larotrectinib for the treatment of TRK fusion solid tumors | Theodore W. Laetsch & Douglas S. Hawkins | 2019 |
Sorafenib: key lessons from over 10 years of experience | Bernard Escudier, Francis Worden & Masatoshi Kudo | 2019 |
Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors | Amro Elshoury, Amanda Przespolewski, Jeffrey Baron & Eunice S. Wang | 2019 |
Anti-BCMA antibodies in the future management of multiple myeloma | Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Meletios Athanasios Dimopoulos & Evangelos Terpos | 2019 |
Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled | Jan Philipp Bewersdor, Maximilian Stahl & Amer M. Zeidan | 2019 |
Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine | Robin Van Den Borg, Alessandro Leonetti, Marcello Tiseo, Elisa Giovannetti & Godefridus J. Peters | 2019 |
Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology | Gabriele Di Sante, Jessica Pagé, Xuanmao Jiao, Omar Nawab, Massimo Cristofanilli, Emmanuel Skordalakes & Richard G Pestell | 2019 |
Capmatinib for the treatment of non-small-cell lung cancer | Johan Filip VansteenkisteORCID Icon,Charlotte Van De Kerkhove,Els Wauters &Pierre Van Mol | 2019 |
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib | Christopher P Wilding, Mark L Elms, Ian Judson, Aik-Choon Tan, Robin L Jones & Paul H Huang | 2019 |
Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies | Lingaku Lee, Tetsuhide Ito & Robert T Jensen | 2019 |
The prognostic role of circulating tumor cells in colorectal cancer | Lahiri Kanth Nanduri, Barbara Hissa, Jürgen Weitz, Sebastian Schölch & Ulrich Bork | 2019 |

